GlassScriptPhysician profile
Tao Li
NPI 1376725143
$906.60
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $124 · 2021: $215.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $304.87 | 2019-2021 | |
| Zyla Life Sciences, INC. | $182.10 | 2019-2020 | |
| Boston Scientific Corporation | $73.96 | 2019-2021 | |
| Pfizer INC. | $61.00 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.99 | 2019 | |
| Almatica Pharma LLC | $30.00 | 2021 | |
| Allergan, INC. | $25.13 | 2021 | |
| Daiichi Sankyo INC. | $23.77 | 2019 | |
| Baudax Bio INC. | $23.52 | 2020 | |
| Stryker Corporation | $18.80 | 2020 | |
| Radius Health, INC. | $18.23 | 2019 | |
| Shionogi INC | $15.11 | 2019 | |
| Indivior INC. | $13.40 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.33 | 2021 | |
| Medtronic, INC. | $12.98 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $11.60 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.52 | 2020 | |
| Amgen INC. | $11.28 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tao Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.